- Home
- DTSS vs BCTX Comparison
DTSS vs BCTX Comparison
Compare DTSS & BCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DTSS
- BCTX
- Stock Information
- Founded
- DTSS 2014
- BCTX 2014
- Country
- DTSS China
- BCTX Canada
- Employees
- DTSS N/A
- BCTX N/A
- Industry
- DTSS Computer Software: Prepackaged Software
- BCTX Biotechnology: Pharmaceutical Preparations
- Sector
- DTSS Technology
- BCTX Health Care
- Exchange
- DTSS Nasdaq
- BCTX Nasdaq
- Market Cap
- DTSS 14.2M
- BCTX 15.8M
- IPO Year
- DTSS N/A
- BCTX N/A
- Fundamental
- Price
- DTSS $2.14
- BCTX $3.61
- Analyst Decision
- DTSS
- BCTX Strong Buy
- Analyst Count
- DTSS 0
- BCTX 1
- Target Price
- DTSS N/A
- BCTX $32.00
- AVG Volume (30 Days)
- DTSS 63.5K
- BCTX 42.8K
- Earning Date
- DTSS 05-12-2025
- BCTX 03-12-2025
- Dividend Yield
- DTSS N/A
- BCTX N/A
- EPS Growth
- DTSS N/A
- BCTX N/A
- EPS
- DTSS N/A
- BCTX N/A
- Revenue
- DTSS $47,284,153.00
- BCTX N/A
- Revenue This Year
- DTSS N/A
- BCTX N/A
- Revenue Next Year
- DTSS N/A
- BCTX N/A
- P/E Ratio
- DTSS N/A
- BCTX N/A
- Revenue Growth
- DTSS 117.51
- BCTX N/A
- 52 Week Low
- DTSS $1.65
- BCTX $0.35
- 52 Week High
- DTSS $9.78
- BCTX $7.87
- Technical
- Relative Strength Index (RSI)
- DTSS 46.85
- BCTX 46.14
- Support Level
- DTSS $2.14
- BCTX $3.44
- Resistance Level
- DTSS $2.44
- BCTX $4.36
- Average True Range (ATR)
- DTSS 0.14
- BCTX 0.38
- MACD
- DTSS -0.00
- BCTX -0.09
- Stochastic Oscillator
- DTSS 12.50
- BCTX 12.69
About DTSS Datasea Inc.
Datasea Inc is a technology company. Its offers provides acoustic business services (focusing on high-tech acoustic technologies and applications such as ultrasound, infrasound, and Schumann resonance), 5G application services (5G AI multimodal digital business), and other products and services to various corporate and individual customers. The business activity of the group functions through China.
About BCTX BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.